Michael Thurn is an experienced executive in the pharmaceutical and biotechnology sectors, currently serving as Managing Director and Chief Executive Officer at Neurizon since May 2024 and as Co-Founder & Director at MARP Therapeutics Pty Ltd since December 2021. Previously, Michael held leadership positions including Chief Executive Officer at PharmAust Ltd from September 2023 to April 2024, and Chief Executive Officer at Mimetica Pty Limited from September 2006 to November 2021. Additional roles include Chief Operating Officer at Botanix Pharmaceuticals and Cytopia Research Pty Ltd, as well as Head of Drug Development at Xenome Limited. Early career experience includes important positions such as Senior Toxicologist at TGA and Anti-cancer Program Team Leader at Novogen. Michael holds a Doctor of Philosophy (Ph.D.) from the University of Technology Sydney.
This person is not in any teams
This person is not in any offices
Neurizon
1 followers
Neurizon Therapeutics Limited (ASX: NUZ), formerly known as PharmAust, is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.